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Suppression of the immune system has been constantly reported in the last years
as a classical side effect of opioid drugs. Most of the studies on the immunological
properties of opioids refer to morphine. Although morphine remains the “reference
molecule,” other semisynthetic and synthetic opioids are frequently used in the clinical
practice. The primary objective of this review is to analyze the available literature on
the immunomodulating properties of opioid drugs different from morphine in preclinical
models and in the human. A search strategy was conducted in PubMed, Embase,
and the Cochrane databases using the terms “immunosuppression,” “immune system,”
“opioids,” “Natural killer cells,” “cytokines,” and “lymphocytes.” The results achieved
concerning the effects of fentanyl, methadone, oxycodone, buprenorphine, remifentanil,
tramadol, and tapentadol on immune responses in animal studies, in healthy volunteers
and in patients are reported. With some limitations due to the different methods used to
measure immune system parameters, the large range of opioid doses and the relatively
scarce number of participants in the available studies, we conclude that it is not correct
to generalize immunosuppression as a common side effect of all opioid molecules.
Keywords: morphine, immunosuppression, fentanyl, buprenophine, oxycodone, methadone, tramadol, tapentadol
Opioids remain the most effective and used drugs for severe pain treatment despite several
negative aspects of poor health are often associated with their use. Moreover, opioids are the basic
treatment for acute pain after surgery and for chronic pain, including cancer and non-cancer
related pain. Among their well-known side effects, suppression of the immune system has been
increasingly reported (1–3). In the last years the use of opioids increased and the concern that their
immunological effects during and after surgery may impact on disease processes, such as bacterial,
viral infections or cancer (2, 4), increased in parallel.
Moreover, opiates are also illicit drugs of abuse. The potential immunosuppressive effects of
heroin and of the opioids used for opioid abuse treatment, such as methadone and buprenorphine,
are of relevance since higher susceptibility to infection, or worst disease progression is reported in
opioid addicted subjects (5, 6).
Numerous mechanisms at the basis of the effects of opioids on immune cells have been
described. In vivo, the effects of morphine on immunity are mediated at both central and peripheral
sites. Morphine binds to opioid receptors (OR) expressed on the cells of the immune system or
on receptors within the nervous system. Opioid receptor activation in the central nervous system
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may modulate peripheral immunity via the hypothalamic
pituitary adrenal axis and the autonomic nervous system (1–
3, 7). This double modulation makes it somehow difficult to
reconcile results obtained in vitro or in vivo with opioids, that
often are different.
Most of the studies available on the immunological properties
of opioids refer to morphine. Although morphine remains the
“reference molecule,” other semisynthetic and synthetic opioids
are frequently used in the treatment of pain in patients. It is
therefore important to achieve a careful analysis of the different
opioid drugs in order to understand whether they all display
immunosuppressive properties. Although most data derive from
preclinical studies, it is emerging that differentl opioids do not
share the same immunosuppressive effects (1–3, 8).
The main objective of this review is to analyze the available
literature on the immunomodulating properties of opioids drugs
different from morphine. With this aim, we do not analyze in
details the immune effects of morphine, since several excellent
reviews have been published in recent years (1–3, 6–10).
However, especially in the animal studies the effects of each
opioid drug is often compared to that of morphine, and therefore
the impact of morphine on immunity is indirectly reported.
Figure 1 shows the structural formulae of the drugs considered
in the present review.
In order to obtain the data, the databases Ovid MEDLINE
(PubMed) and Embase (Ovid MEDLINE(R), Cochrane database
and Web of Knowledge were searched using specific terms.
FIGURE 1 | Structures of the opioid drugs described in the review. Oxycodone and buprenorphine are semisynthetic opioids; fentanyl, remifentanil, methadone,
tramadol, and tapentadol are synthetic opioids.
To search for opioids, the terms used were: opioid OR opiate
OR morphine OR buprenorphine OR methadone OR tramadol
OR tapentadol OR oxycodone OR heroin OR fentanyl OR
remifentanil. They were combined with a search for immunity:
including immune∗ OR Lymphocytes OR NK cell OR T cell
OR cytokines OR immunosuppression. No limit for human or
animal studies were added. All titles and abstracts were reviewed
to assess their relevance for inclusion and reference lists from
reviews and key publications were manually searched. Articles
were also identified through searches of the authors’ own files and
previous reviews on the topic.
Two authors (PS and SF) performed literature searches and
reviewed all titles and abstracts. Full papers were retrieved and
the full texts analyzed by authors.
FENTANYL
Fentanyl is a potent synthetic full agonist of the mu opioid
receptor (MOR). It has a very short half-life and for this reason it
has been for many years used mainly for the management of pain
during surgery procedures. Only more recently the availability of
a transdermal device allowed its use for chronic pain.
The effects of fentanyl on several immune parameters have
been explored in animal and human studies after both acute and
chronic treatment (1, 2, 7). Considering the wide use of this
opioid in the perioperative period, several studies focused on
its immunomodulatory effects at this time. This postoperative
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period is accompanied by immune suppression due to the
interaction of several factors including analgesics used for
pain treatment (1, 2, 11–13). An impaired immunity in the
period may slow recovery, and may participate in the risk of
developing infections and sepsis. Moreover, in cancer surgery,
immunosuppression in the perioperative period is critical for the
survival of cancer cells, due to the importance of the role of
cell-mediated immunity in reducing micrometastatic formation
(1, 2, 14, 15).
Preclinical Studies
The immunopharmacological profile of fentanyl is similar to
that of morphine. In preclinical studies, fentanyl has been
reported to induce a dose-related immunosuppression (16). In
rodents, continuous fentanyl infusion suppresses NK activity,
lymphocyte proliferation, and cytokine production (16). Since
NK activity is very important for the control of metastasis,
several studies investigated the effect of fentanyl at doses
clearly able to depress NK activity on the development of
experimental tumor metastases (16–18). In these experiments
animals were injected with a tumor cell line (MADB106
mammary adenocarcinoma) that is retained in the lung and
grows as metastases. The cell tumor retention in the lungs
inversely correlates with the efficacy of NK activity to destroy
cancer cells. In these animals, it was shown that when fentanyl
induced a dose-dependent decrease of NK cytotoxicity, the
number of lung metastases increased (17, 18). Surgery and
peri-surgery pain itself induces immunosuppression. Therefore,
the effect of fentanyl on immune responses and metastasis
was analyzed also following experimental surgery. While in
two papers fentanyl and surgery-induced immunosuppression
become additive (16, 19), in the work by Forget et al. (18) fentanyl
did not worsen surgery-induced metastatic growth but did not
prevent it. Molina-Martínez et al. (20) compared the effects
of prolonged morphine and fentanyl treatment on macrophage
function and TNF production. Both opioids significantly
inhibited LPS-induced TNF production by macrophages at
the same doses at which they produce antinociceptive effects.
However, chronic opioid administration resulted in the loss
of opioid-induced immunosuppressive effects indicating the
development of tolerance. Interestingly, in the case of morphine,
tolerance to the antinociceptive and immunosuppressive effects
was parallel while in the case of fentanyl a significant
analgesic effect was still present when the immunosuppressive
effects had disappeared. The development of tolerance to the
immunosuppressive effects of fentanyl has been reported also in
Martucci et al. (16), suggesting that it is difficult to generalize the
immunopharmacological properties of fentanyl since they may
depend on dosage and length of treatment.
Human Studies
The immunosuppressive properties of fentanyl have been
consistently observed also in the human. The drug affects cellular
immune responses and cytokine production in patients and
healthy volunteers in a dose related fashion (1, 2, 21–24).
Most of the studies deal with fentanyl acute treatment during
or after surgery.
The effect of high (75–100 µg/kg) or low (1–5 µg/kg)
doses of fentanyl on natural killer cell cytotoxicity (NKCC) was
assessed in 40 patients in the perioperative period (23). This
study showed that both doses induced an inhibition of NK
cytotoxicity on the first postoperative day; however, patients
on the low dosage recovered faster, while patients on higher
doses still showed reduction of immune parameters 48 h after
surgery. These results were confirmed by Yardeni et al. (24),
who studied the effect of high (70–100 µg /kg), intermediate
(23–30 µg/kg), and low (2–4µg/kg) doses of fentanyl on immune
responses during the postoperative period in 60 patients. High
and intermediate doses of fentanyl significantly depressed the
levels of the proinflammatory cytokines IL-1 and IL-6 compared
to patients on the low dose.
In a randomized controlled trial of 25 patients undergoing
neck surgery, NK activity was assessed in patients treated with
either fentanyl of flurbiprofen. In fentanyl treated patients
NK cell cytotoxicity was suppressed more than in patients
treated with flurbiprofen on day 1, but not day 2 post-
operatively (25). More recently, the effect of fentanyl was assessed
in 50 patients undergoing breast cancer resection who were
given either propofol-remifentanil anesthesia with postoperative
ketorolac analgesia or sevoflurane-remifentanil anesthesia with
postoperative fentanyl for pain treatment (Sevoflurane-fentanyl
group) (26). NK cytotoxicity was measured before and 24 h after
surgery. In the sevoflurane-fentanyl group a significant inhibition
of NK activity was measured, while no alterations were observed
in the other treatment group. The authors also evaluated cancer
recurrence or metastasis every 6 months for 2 years after surgery
and did not find significant differences between groups.
Somehow in contrast with the suppressive effects of fentanyl
on NK activity in patients, two healthy volunteer studies
reported that acute intravenous fentanyl increased NK cell
cytotoxicity, an effect that was shown to be due to an increase
in the proportion of NK cells in the circulation rather than
an increase in the cytotoxicity of individual NK cells (22,
27). The clinical significance of these observations remains to
be understood.
METHADONE
Methadone is synthetic 3,3-diphenylpropylamine opioid with a
unique pharmacological profile. It primarily acts at the MOR but
also activates kappa (KOR) and delta (DOR) receptors.Moreover,
it also binds N-methyl-D-aspartate receptor as a weak antagonist
(28). Methadone is a potent and long-acting opioid and its
PK and PD characteristics have made it the most used opioid
for substitution therapy in opioid dependence (29). However,
methadone is also a valuable drug in the management of chronic
pain especially in cancer pain. Its efficacy as an NMDA antagonist
suggests its use in neuropathic pain as well (28).
A small number of studies analyzed the impact on immunity
of methadone in the experimental animal, while a few papers
reported the immune status of opioid addicted subjects on
methadone maintenance therapy in comparison to heroin
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abusers. No studies were found on the immune profile of
methadone in chronic pain patients.
Preclinical Studies
Old studies from the nineties of the last century showed that
chronic methadone treatment in rats did not affect either
Trichinella nor Listeria infection (30, 31), in contrast to chronic
morphine treatment that significantly augmented infection. No
effect was observed on antibody production after methadone
treatment. Indeed a paper by Van De Laan (32) indicated that
methadone prolonged treatment increases cellularity of spleen
and lymph-nodes.
Methadone is administered as a racemic mixture of
(R)-(-)- and (S)-(+)-enantiomers, with only (R)-(-)-methadone
possessing opioid receptor agonist activity. Hutchinson et al.
(33) investigated the specific immunomodulatory effect of
the (R)-(–)–or(S)-(+)-enantiomer in vivo administration
to mice and found that the (S)-(+)-enantiomer that is
devoid of analgesic efficacy caused significantly greater
inhibition of lymphoproliferation than the (R)-(_)- or racemic
methadone. The authors suggested that methadone-induced
immunomodulation was not a classical opioid response but
might be mediated by “non classical,” not yet identified, opioid
receptors at central level.
The effect of methadone-prolonged treatment on macrophage
functionality and its ability to influence contact hypersensitivity
and antibody production was studied by Filipczak-Bryniarska
(34). From this work, that compared several opioids, it emerged
a decrease of macrophage function, alteration of antibody
production and of contact hypersensitivity in methadone treated
mice. However, the percentage of inhibition was lower than that
of morphine and fentanyl.
Interestingly methadone was found to protect mice
from experimental autoimmune encephalomyelitis (35).
The drug reduced clinical signs of the disease, the level of
inflammatory cytokines produced by T cells and recruitment
of inflammatory cells into the spinal cord. The authors
conclude that opioid receptor signaling may be beneficial in the
context of autoimmune neuroinflammation (35). This paper
suggests therefore that the mild immunosuppressive activity of
methadone may be exploited in autoimmune diseases.
In conclusion, from the preclinical studies reported
methadone exerted a weak immunosuppressive activity.
Human Studies
In vitro
Methadone was included in a study that compared the effect
of several opioids added in vitro to human cells and that
evaluated neutrophil and monocyte phagocytosis and oxidative
burst responses, NK cell cytotoxicity and T cell activation
in vitro (36). Confirming what was observed in the animal
experiments, in contrast to the morphine and fentanyl effects,
in vitro methadone did not influence monocyte and neutrophil
phagocytosis. None of the drugs tested modified NK activity,
but methadone significantly decreased IL-6 production by T
lymphocytes. As already reported above, the in vitro experiments
are only partially representative of opioid effects in vivo, due to
the fact that some effects are mediated by the activation of the
MOR in the central nervous system.
Morphine and methadone are often used for treatment of
neonatal abstinence syndrome (NAS). Therefore, Chavez-Valdez
et al. (37) analyzed whether clinically relevant concentrations
of different opioids may modify cytokine levels in cultured
whole blood from preterm and full-term infants. All three MOR,
KOR, DOR genes were expressed in mononuclear cells from
preterm and full-term infants. Morphine andmethadone, but not
fentanyl, decreased LPS stimulated IL-1b, IL-6, IL-10, IL-12p70,
and TNF.
Finally, in the elegant work by Borner (38) in vitromethadone
was reported to increase the production of the Th2 cytokine IL-
4, differently from morphine and buprenorphine. In this paper
the authors identify the transcription factor NFAT and AP1
at the basis of methadone-induced IL-4 stimulation. Moreover,
methadone and fentanyl were able to efficaciously induce
MOR internalization on a T cell line (Jurkat T cells), while
buprenorphine and morphine did not. Therefore, the authors are
the first to suggest that the immunomodulating properties of the
different opioids may depend on their ability to activate different
signaling pathways after MOR stimulation.
In vivo
The hypothesis that significant alterations of cellular immunity
in heroin abusers might be normalized by switching to long-term
methadone treatment was proposed several years ago in a first
paper that presented the genetic damage provoked by different
opioids in T lymphocytes (1, 39). Subsequent studies evaluated
other immune responses, such as NK cytotoxicity, T cell subset
number and function and phagocyte activity in patients under
methadone maintenance treatment in comparison with heroin
abusers (40, 41). The studies also tried to analyze whether the
improvement of immune responses observed with methadone
treatment was dependent on the drug itself or on themodification
of life style that may intervene during the maintenance
treatment. A randomized clinical trial reported that the switch
to methadone or buprenorphine treatment restored the immune
function depressed by heroin in addicted individuals (40).
Moreover, a controlled methadone or buprenorphine therapy
also normalized the Th1/Th2 balance that was significantly
unbalanced during chronic heroin use (41). The beneficial effect
of methadone maintenance on immune system responses of
heroin abusers has been consistently reported also more recently
(42–44). Participation in methadone maintenance treatment was
protective against hepatitis C incidence among illicit drug users
and methadone exerted a dose-response protective effect on
hepatitis C incidence (42). Naïve HIV-infected individuals using
heroin and receiving methadone opioid substitution or controls
(who never used opioids) were studied in the paper by Meijerink
(44). Whole blood obtained from the two groups was stimulated
withMycobacterium tuberculosis, Candida albicans, and LPS and
cytokine production was determined. The cytokine production
stimulated with LPS was significantly down-regulated in HIV-
infected heroin users while inmethadone users cytokine response
was not different from subjects who never used opioids. Similarly,
methadone treatment was able to re-establish the number and
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the expression markers of dendritic cells that were significantly
altered in a cohort of heroin drug abusers (43). Surprisingly
in another work, heroin abusers on methadone maintenance
treatment had IL-1β, IL-6, and IL-8 levels significantly higher
than in control healthy subjects. In addition, a significant
correlation was observed between the plasma TNF-α and IL- 6
levels, the dose and the duration of methadonemaintenance (45).
The authors suggest that methadone maintenance treatment may
induce long-term systemic inflammation.
Several factors may participate in the immune system
amelioration, such as the different immunopharmacological
profiles of the opioids used, the absence of withdrawal episodes,
and a safer use of contaminated drug syringes or other
instruments. Unfortunately, due to the paucity of controlled
longitudinal epidemiological studies, based on the available
data it is not possible to reach an answer whether opioid-
induced immunosuppression or behaviors associated with drug
abuse may be responsible for higher incidence of infections in
addicted patients.
OXYCODONE
The semisynthetic opioid oxycodone is one of the most
prescribed in Europe and the United States both for acute and
chronic pain and has been recently recognized as abused drug.
Oxycodone is a relatively selective MOR agonist, its affinity for
the MOR is less than that of morphine or methadone but it
exerts a similar antinociceptive effect. This discrepancy has been
explained on the basis of the pharmacokinetic properties of the
molecule that passes the blood brain barrier easily. The analgesic
effect is due in large part to the parental molecule itself. However,
oxycodone is biotransformed in the liver by cytochrome into
active metabolites with higher MOR affinity that participate in
its analgesic efficacy (46).
Considering the elevated number of patients who had received
oxycodone it is surprising the paucity of works concerning the
immunomodulating effect of the drug. However, the papers
published consistently report that this molecule has only a
minimal impact on immunity, which in all cases is much lower
than that of morphine or fentanyl.
Preclinical Studies
The first evidence of the neutral immunopharmacological profile
of oxycodone comes from the paper by Sacerdote et al. (47), a
structure-related activity study that compared in vivo the impact
of natural and semisynthetic opioids on lymphoproliferation, IL-
2 production, and NK activity in the mouse. The data indicate
that the C6 carbonyl substitution and the presence of a C7-8
single bond, like in oxycodone, potentiates the antinociceptive
effect, but abolishes immunosuppression.
In a series of papers the in vivo treatment with oxycodone
on macrophage functionality was studied (48, 49). Although
not completely devoid of effect, oxycodone expressed weaker
immunomodulatory properties than morphine and the authors
concluded that oxycodone seems to be a safer opioid for chronic
therapy. However, in one single study conducted in vitro with
mouse splenocytes (50), an inhibitory effect of oxycodone was
reported on lymphoproliferation with an inverted bell shaped
curve, with only few intermediate concentrations active. Indeed
the limitation of the study remains the fact that the in vitro
experiments are only partially representative of opioid effects in
vivo, due the to the fact that some effects are mediated by the
activation of the MOR in the central nervous system.
Human Studies
Boland (36) compared the effect of several opioids added in
vitro to human cells and evaluated neutrophil and monocyte
phagocytosis and oxidative burst responses, NK cell cytotoxicity
and T cell responsiveness. Oxycodone did not influence
monocyte and neutrophil phagocytosis nor NK activity, but
it decreased IL-6 production by T lymphocytes. As reported
above, oxycodone has an active metabolite that participates in the
analgesic effect. Obviously in the in vitro studies this component
is not present, limiting in part the significance of the results.
Only three studies were found that tried to assess the
potential immunomodulatory effect of oxycodone in patients.
General immune responses and local responses in the surgical
wound were measured in children who underwent surgery (51).
Bolus doses of diclofenac intravenously and rectally, continuous
i.v. oxycodone infusion or continuous epidural infusion of
bupivacaine—fentanyl were applied for pain treatment. The
authors conclude that all post-operative pain treatments had
similar effects on systemic and local immune responses with
minor, probably clinically irrelevant differences.
Suzuki et al. (52) performed a retrospective study that
analyzed the correlation between morphine or oxycodone
administration and the presence of infections in patients
with cancer pain. In this work no measurement of immune
functionality was indeed present. This study enrolled 841 patients
receiving one opioid continuously for more than 10 days. A
significant higher number of patients treated with morphine
developed infections in comparison to patients with oxycodone.
These results indirectly suggested that morphine- induced
immunosuppression may participate to infections in patients
with cancer pain. More recently, a clinical study evaluated the
effect of oxycodone hydrochloride injection on the immune
responses of patients who underwent resection of rectal cancer
under general anesthesia (53). At the end of surgery, patients
were injected with 5mg of oxycodone or with 5mg of morphine
and the number of T cell subsets and NK cells was assessed
by flow cytometry. Both opioids exerted inhibitory effects on
immune function but oxycodone had a smaller effect than
morphine and the immunosuppression was short lasting, since
the responses normalized by 6 h after treatment.
In conclusion from the scarce studies available the
immunosuppressive effects of oxycodone, although present,
appears always weaker than those of morphine and fentanyl.
BUPRENORPHINE
Buprenorphine is a semisynthetic thebaine derivative acting as
a partial agonist of MOR, an ORL-1 full agonist and KOR
and DOR antagonist. Buprenorphine has a high affinity for the
opioid receptors, low intrinsic efficacy and it is characterized
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by a slow receptor binding kinetics. Due to the complex profile
of this molecule at opioid receptors, its pharmacological profile
is often different from the other opioid agonists (54). The
molecule in transdermal patch is used for the treatment of
chronic pain. Moreover, in the last years it is increasingly used
for maintenance treatment of heroin addiction as an alternative
to methadone (55).
Preclinical Studies
Experimental animal work conducted by several research
groups points to a safe profile of buprenorphine on immune
responses when administered both acutely and chronically.
Gomez Flores and Weber (56, 57) had shown that in the rat
after the acute injection of equianalgesic doses of buprenorphine
and morphine into the mesencephalic peri-acqueductal gray
(PAG), buprenorphine did not alter NK cell cytotoxicity, T
cell and macrophage function, while morphine significantly
suppressed these functions. Similar results were also reported
after continuous buprenorphine delivery in comparison with
fentanyl (16). In a model of surgery stress in the rat,
buprenorphine prevented all the biochemical, endocrine and
immune modifications caused by pain, differently from the
clearly evident fentanyl induced immunosuppression in the same
experimental model (19).
The final effect of opioid drugs on immunity depends on
several aspects: the intrinsic immunosuppressive property of
the drug and the prevention of pain and neuroendocrine
activation. Pain is a physical and psychological stressor that
causes activation of the HPA axis and the sympathetic nervous
system and can have a negative impact on immunity (58). In a
rat model of experimental surgery the presence of post-operative
pain increased corticosterone levels, decreased NK cytotoxicity
and facilitated the spreading of metastasis of the NK-sensitive
tumor MADB106 (19, 57). Morphine and fentanyl did indeed
relieve pain, but also stimulated the HPA axis, decreased NK
activity and did not prevent surgery-induced metastasis. In
contrast, equianalgesic doses of buprenorphine prevented the
HPA activation and immune system depression and controlled
the increased number of tumor metastasis (19).
Human Studies
Very few studies addressed the impact of buprenorphine on
immune parameters in the human. In in vitro experiments using
cells from human volunteers, buprenorphine had only limited
effects on neutrophil, monocyte phagocytosis and oxidative burst
and did not modify cytokine production (36). Recently two
elegant studies (59, 60) showed the ability of buprenorphine to
reduce CCL2-induced chemotaxis and transmigration into the
brain of a sub class of monocytes, the CD14+CD16+ monocytes
that play an important role in HIV sustained neuroinflammation
in AIDS patients. In these papers the authors also demonstrate
the presence of functional MOR and KOR on this monocyte
subtype. The clinical relevance of these results is positively
discussed by the authors, who suggest the possibility that in HIV-
opioid addicted patients, buprenorphine maintenance treatment
may help to prevent neuroinflammation and neurological
dysfunction observed in AIDS patients.
Two studies are published on the effect of buprenorphine
treatment in vivo on immunity in humans, recruiting drug
abusers who were on chronic maintenance with the drug
for opioid dependence (40, 41). Although buprenorphine
doses were quite high (mean dose 9.3 ± 2.3 mg/day), a
significant amelioration of immune parameters was registered
in comparison with those measured before starting the
buprenorphine treatment. However, as already discussed for
methadone, several factors may contribute to the positive effect
on immunity, besides the immunopharmacological profiles of the
different drugs, such as the control of withdrawal episodes and
the change of habits linked to intravenous injections.
REMIFENTANIL
Remifentanil is an ultra-short-acting MOR agonist used in
general anesthesia since it efficaciously and rapidly controls the
autonomic, hemodynamic and somatic responses to noxious
stimuli. Due to its molecular structure, blood esterases hydrolyze
it, resulting in fast metabolism, and fall in serum concentrations
after interruption of the infusion (61). The definition of its
immunomodulating properties in the perioperative period could
be of particular interest.
Preclinical Studies
Sacerdote et al. (62) evaluated the effects of remifentanil
continuous infusion on immune function in the rat and
reported suppression of the immune response, characterized
by a significant reduction of NK cytotoxicity, lymphocyte
proliferation, and cytokine secretion. In another rat study
remifentanil infusion also significantly reduced activation and
cytokine production from broncho-alveolar neutrophils and
macrophages in LPS induced lung injury (63).
Human Studies
In accordance with what was observed in the rat, the in
vitro addition of remifentanil to human neutrophils from
healthy volunteers induced a dose dependent reduction of
proinflammatory cytokine production (64, 65). In contrast low-
dose (0.02–0.04 µg/ kg/min) remifentanil infusion in healthy
volunteers did not cause any significant alteration in the number
nor the cytotoxicity of NK cells after an 8-h infusion (66). These
results once more suggest that depending on the cell type, the
parameters and the in vivo or in vitro administration, the effect
of opioids on immunity may be very different. Finally, cytokine
secretion was reported to be reduced by remifentanil also in
patients who underwent coronary artery bypass graft surgery.
Interestingly in this study remifentanil (0.3–0.6 µg/kg per min)
suppressed mainly proinflammatory cytokines such as IL-6, TNF,
and IFN-γ, but did not significantly affect the anti-inflammatory
cytokine IL-10; the authors suggest that remifentanil infusion
may blunt the inflammatory response that may take place after
cardiac surgery with cardiopulmonary bypass (67).
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TRAMADOL
Tramadol is an opioid drug with pharmacodynamics
characteristics distinct to those of the classic opioids. It is
a weak opioid that also blocks serotonin and noradrenaline
reuptake. The tramadol metabolite M1 binds MOR with
low affinity, while the parental molecule inhibits serotonin
and noradrenaline uptake causing the activation of descending
inhibitorymonoaminergic pathways (68). Its effects on immunity
were analyzed in preclinical and clinical studies with consistent
results (1).
Preclinical Studies
Tramadol did not induce any immunosuppressive effect either
after acute or chronic treatment. When administered acutely
to normal animals tramadol induced a clear immunoenhancing
effect on several immune parameters such as NK cytotoxicity,
proliferation of lymphocytes and cytokine production (69). In the
animal studies, using specific antagonists, it was demonstrated
that the immunostimulating activity of tramadol has to be
ascribed to its serotoninergic activity (70).
The effects of tramadol on immunity was thereafter evaluated
in different animal models of pain in direct comparison with
morphine. In a rat model of neuropathic pain, tramadol
did not affect the NK activity, while morphine depressed it
(71). As already reported, pain associated with surgery is one
important factor that participates in surgical stress-induced
immunosuppression, and in particular NK activity is extremely
sensitive to peri-operative stress (11, 58). Equi-analgesic doses
of tramadol and morphine were studied in a preclinical
model of surgery-induced suppression of NK activity; only
tramadol prevented the reduction of NK cytotoxicity (72). Both
tramadol andmorphine similarly relieved pain, but tramadol also
possessed intrinsic immunostimulating properties, that helped to
protect NK activity (72).
Human Studies
This profile of tramadol was confirmed also in human
studies (73–75).
In in vitro studies, tramadol did not affect human
polymorphonuclear activity from healthy volunteers (75).
The impact of morphine or tramadol on the immune function
was studied in patients who underwent surgery and were treated
for post-operative pain (73). In morphine treated patients, a
prolonged reduction of immune function was measured. In
contrast, patients treated with tramadol at equianalgesic dose
with morphine showed a faster and full recovery of immune
parameters depressed by surgery (73). The good profile of
tramadol on immunity was reported in a different trial where
morphine and tramadol were again given to provide analgesia
after surgery (74).
TAPENTADOL
Tapentadol is a novel, centrally acting analgesic drug used for
treating moderate-to-severe pain (76). It is characterized by a
dual mechanism of action; it binds with low affinity to MOR as
an agonist and also inhibits noradrenaline reuptake (77). Both
mechanisms contribute synergistically to its analgesic effect, thus
resulting in analgesia with less opioid related side effects.
Only one study examined the impact on immune responses
of this opioid in the mouse in comparison to morphine (78). In
normal animals, consistently with what would be expected for
the lower affinity of tapentadol for MOR, both the acute and
chronic administration of the opioid did not affect lymphocyte or
macrophage cytokine production, whereas morphine decreased
all cytokines measured. The modulation by morphine and
tapentadol of peripheral cytokine production was evaluated also
in mice suffering from chronic pain consequent to sciatic nerve
ligation. The presence of chronic pain itself had a negative impact
on cytokines. Both morphine and tapentadol exerted a similar
and satisfactory analgesic activity, but only in tapentadol treated
mice a significant restoration of the anti-inflammatory cytokines
was present. The authors concluded that acute and chronic
tapentadol is neutral on cytokine production, and hypothesized
that the synergy of the two mechanisms of action of tapentadol,
which play an important role in analgesia, is not relevant for the
immunosuppressive properties.
Differently from tramadol, tapentadol did not
enhance any immune parameter, confirming that the
immunostimulating activity of tramadol depends mainly
on the serotoninergic mechanisms.
Human Studies
We could not find any clinical work examining the effects of
tapentadol on immunity.
CONCLUSIONS
While for decades opioids have been considered as a class of
drugs with similar clinical and side effects, in the last years it is
increasingly emerging that the different molecules have peculiar
characteristics that differentiate them. The immunosuppressive
activity is certainly one of the side effects that more than others
differentiates opioids. The mechanisms at the basis of these
differences need to be studied in detail and at the moment
only suggestions or hypotheses can be put forward. The many
observations reported of different results obtained when the
opioids are added in vitro or administered in vivo point to the
importance of both a direct effect mediated by opioid receptors
expressed by immune cells and indirect effects due to MOR
activation in the nervous system (1–3, 10).
What has been well-demonstrated in a series of animal studies
is that in the absence of MOR the immunosuppressive effect
of morphine is lost (10, 79, 80). This fact may explain why
opioids with low opioid receptor affinity such as tramadol or
tapentadol have a lower immunosuppressive activity in animal
and human studies at analgesic doses. Their analgesic effect
is sustained by the combination in the same molecule of
more mechanisms of action (such as opioid receptor binding
and monoaminergic stimulation), but the additive/synergistic
mechanisms that are important for analgesia do not have a role
in the immunosuppression.
Frontiers in Immunology | www.frontiersin.org 7 December 2019 | Volume 10 | Article 2914
Franchi et al. Immunomodulation by Different Opioids
TABLE 1 | Summary of the effects of opioid drugs on immunity.
Preclinical studies Human studies
In vitro In vivo In vitro In vivo
Fentanyl n.d. ↓ (16–20) ↔↓(22, 36) ↓[POP](23–26)
↑[h.v.] (27)
Methadone ↓(33)
↔(30,
31)
↓ (34, 35)
↔ (32–34)
↓(36, 37)
↔ (36)
↔ [MMT] (39–44)
Oxycodone ↓ (50) ↔ (47–49) n.d. ↓[POP] (53)
↔ [POP and cancer
pain] (51–53)
Buprenorphine n.d. ↔(16, 19, 56, 57) ↓↔ (59, 60) ↔ [BMT] (40, 41)
Remifentanil n.d. ↓ (62, 63) n.d. ↓ [POP](64, 65, 67)
↔ [POP](66)
Tramadol n.d. ↑ (69–72) ↔(75) ↔↑[POP](73, 74)
Tapentadol n.d. ↔(78) n.d. n.d.
↓ significant decrease of at least one immune parameter.
↑significant increase of at least one immune parameter.
↔ no effect.
↓↔ different effect on different immune parameters.
n.d., not determined.
POP, peri–operative period.
h.v., healthy volunteers.
MMT, methadone maintenance treatment of opioid addicts.
BMT, buprenorphine maintenance treatment of opioid addicts.
() numbers in brackets are corresponding references.
However, this explanation cannot be applied to other potent
opioids such as buprenorphine, oxycodone or methadone. The
recent advances in the comprehension of opioid pharmacology
and the biology of the opioid receptors and their signaling
(81, 82) pathways may help to investigate the reasons for these
differences. The term “biased agonism” (or functional selectivity)
refers to the ability of different ligands of the same receptor
to stabilize the receptor in different active states. This different
stabilization may lead to the activation of different intracellular
pathways: a biased agonist preferentially activates one signaling
pathway rather than another (83, 84).
Biased agonists of GPCRs, such as those binding opioid
receptors, might activate G protein-mediated pathways while
other agonists might involve β-arrestin-2. It has been suggested
that analgesia is associated with G-protein pathways, while
arrestin recruitment with some opioid-related adverse effects
(85). Although this aspect is still under debate, some studies
have tested this paradigm evaluating respiratory depression,
gastrointestinal effects or abuse potential, but the impact
of G-protein vs. arrestin activation in immunosuppression
has never been explored. For example unlike opioids such
as morphine, fentanyl and methadone, buprenorphine does
not recruit β-arrestin to the receptor (86) and as described
above buprenorphine has been reported to be devoid of
immunosuppressive properties. Indeed morphine is a balanced
agonist, and its ability to recruit arrestin after receptor binding
is lower than that of fentanyl or methadone that have been
suggested to be a β-arrestin biased compounds (85, 87). However,
morphine and fentanyl have comparable immunosuppressive
activity, while methadone is a weaker immunomodulator and
therefore the concept of biased agonist is not sufficient to
explain differences.
As it is well-known, methadone is characterized by unique
and diverse pharmacologic properties, including NMDA
receptor antagonism, inhibition of serotonin and noradrenaline
uptake and affinity for DOR in addition to MOR (28, 87).
The possible role of these different mechanisms in the
mild immunomodulation induced by methadone has never
been assessed.
A further different aspect is represented by the human studies
conducted in the heroin addicted subjects switched tomethadone
or buprenorphine maintenance. In this situation several variables
may be involved. Short acting opioid drugs such as morphine
and heroin have been shown to deeply affect immune system
(1, 41) while long acting opioids, such as methadone and
buprenorphine, can progressively restore immune function and
cytokine levels (40). An interesting point to be considered is the
observation that during opioid withdrawal several biochemical
and hormonal perturbations are present. These alterations
or fluctuations of hormones and neurotransmitters may be
implicated in opioid-induced immunosuppression (88, 89). It is
therefore possible that the re-establishment of immune responses
that is present with methadone and buprenorphine in contrast to
heroin could partially depend on the constant activation ofMOR.
Consistently with this hypothesis, in a monkey model of HIV
infection the administration of morphine according to a protocol
that prevented withdrawal did not have a negative impact on
immunity and did not worsen HIV disease progression (90).
In contrast, the same authors also demonstrated that an abrupt
discontinuation of opioids precipitated immune dysfunction
(91). It can be hypothesized that the differences in the immune
response observed in drug addicted subjects could be attributed
to the controlled methadone or buprenorphine use pattern
that reduced withdrawal-induced stress (92). Moreover, long
lasting treatments with methadone and buprenorphine are able
to normalize the HPA axis that is altered in heroin abusers
(93, 94). The normalization of the HPA axis could play an
additional role in restoring the altered immune function present
in heroin addicts.
Finally, it must be remembered that besides
pharmacodynamic also pharmacokinetic differences may
be important for the diverse immune effects of opioids. For
example morphine and oxycodone possess active metabolites
that bind MOR, while fentanyl and methadone do not. Indeed
a few studies have demonstrated that morphine-glicuronide
metabolites exert immunosuppressive activity both in the animal
and in cancer patients (95, 96). Considering that during chronic
opioid treatment metabolites can accumulate also this aspect
deserves further attention.
In conclusion, evidence from preclinical, healthy volunteer
and clinical studies suggests that different opioids have a
variable impact on immunity (Table 1). Indeed only morphine,
fentanyl and remifentanil are consistently described as
immunosuppressive both in the animal and in the human.
All other opioid molecules have been found to have a weaker
impact on immunity. In particular convincing data have
been gathered concerning the neutral effect on immunity of
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tramadol and buprenorphine. While for tramadol the lack of
immunosuppressive activity can be due to the lowerMOR affinity
combined with the serotoninergic component, the reasons for
the profile of buprenorphine are not yet clear and only
speculative. The data available on the potential immune effects
of oxycodone are really too few to draw a general conclusion
on this molecule, although some differences from morphine
are present. As far as methadone is concerned, it appears from
animal studies that it may have intrinsic immunosuppressive
properties; however when used as maintenance treatment in
heroin addicted subjects it can restore immune function. As
reported above several variables may be involved in these
beneficial effects. Unfortunately no study on methadone for
chronic pain treatment is available.
With some limitations and caution due to the different
methods used to measure the responses of the immune system,
the large range of the doses applied and the relative scarce
number of participants in the available studies, we can conclude
that it is not correct to generalize immunosuppression as a
common side effect of all opioid molecules.
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